Presenter: Dr. Bin Xie, Executive Director, Immuno-Oncology, LIDE Biotech
Duration: 60 mins
Webcast Date: 03/24/2022
Since the first immune checkpoint blocker ipilimumab was approved by the US FDA in 2011, more drug companies have sought to develop their own immuno therapy drugs. Humanized peripheral blood mononuclear cell (PBMC) reconstitution in immune deficient mice is becoming a valuable model for evaluating therapeutic antibodies, especially bispecific antibodies (BsAbs), which can mediate immune cells as well as target a tumor antigen.
However, this model has several drawbacks, including a limited dosing window due to graft-versus-host-disease and insufficient natural immune cell infiltration. This has hindered wide application of the model in the development of multiple immune checkpoint inhibitors or immune agonists.
To overcome these issues, LIDE has developed a unique human PBMC/cancer cell co-transfer model which can generate three-dimensional huPBMC-infiltrated tumor tissue for immunotherapy. This model has successfully been used to evaluate the biological function of several signaling proteins and biomarkers in multiple cancers, such as melanoma, breast cancer, and lung cancer.
In this webinar, Dr. Bin Xie discusses the current immuno-oncology drug development landscape, different humanized models available for drug testing, evaluates real-world case studies, and describes the investigation of potential mechanisms by imaging mass cytometry.
Key learning objectives:
- Introduction and history of immuno-oncology drug development and the importance of using humanized mouse models to address scientific questions
- Evaluation of current IO platforms and new methods from LIDE, including analysis of several case studies
- Understanding the spatiotemporal interaction between tissue-infiltrating immune cells and cancer cells via imaging mass cytometry
Speaker:
Dr. Xie’s PhD program at Zhejiang University focused on the molecular signaling regulation of innate immunity and identified two key membrane proteins, Siglec-g/10(Cell, 2013) and Rhbdd3 (Nature immunology, 2014). As a postdoctoral researcher at University of Oxford, he moved on to investigate the dynamic interaction between macrophages and lymphocytes in resident tissues and discovered that a novel B cell differentiation regulator, Zbtb18 (Journal of Immunology, 2021) acted as a potential cancer suppressor. Before joining LIDE, Dr. Xie was the Research Director for Shanghai X.B.H Biotech (GV20 oncotherapy), leading efforts to identify novel immuno-oncology targets for drug development.
Register below to watch: